Newsfeeds Archive - Spark Newswire

1 minute read

BridgeBio Pharma Shares One Year Data From Dwarfism Candidate

June 4, 3:29 PM

BridgeBio Pharma revealed results from the PROPEL 2 Phase 2 trial of infigratinib in children with achondroplasia. Key data shows sustained increases in height velocity and improved body proportionality with a good safety profile.

BBIO

1 minute read

Movers
News

Why BridgeBio Pharma Stock Is Trading Lower Tuesday

By Dylan Berman

June 4, 2:01 PM

BridgeBio Pharma, Inc.

BBIO

1 minute read

News

BridgeBio Pharma Reports Phase 2 Results for Achondroplasia Treatment, Investor Call Scheduled

By Benzinga Newsdesk

June 4, 7:33 AM

BridgeBio Pharma, Inc. (NASDAQ:BBIO) (BridgeBio), a commercial-stage biopharmaceutical company focused on genetic diseases, today announced sustained positive results from PROPEL 2, a Phase 2 trial of the investigational

BBIO

1 minute read

BridgeBio Pharma Announces Results Of Five New Analyses Of Clinical Endpoints From Phase 3 ATTRibute-CM Study of Acoramidis In ATTR-CM At ISA

By Benzinga Newsdesk

May 29, 4:03 PM

- Acoramidis treatment resulted in increased serum transthyretin (TTR) levels by Day 28 that were sustained and were correlated with a reduced risk of all-cause mortality (ACM), cardiovascular mortality (CVM), and

BBIO

1 minute read

News

Reported Sunday, BridgeBio Pharma Presented Results From The Exploratory Cardiac Magnetic Resonance Imaging Substudy Of ATTRibute-CM, Its Phase 3 trial Of Acoramidis In ATTR-CM

By Benzinga Newsdesk

April 8, 2:50 AM

- In this exploratory substudy, treatment with acoramidis was associated with possible cardiac structural and functional improvement compared with placebo, with potential cardiac amyloid regression - The data

BBIO

3 minute read

Reliance Steel & Aluminum Posts Upbeat Earnings, Joins JFrog, AppLovin, Shake Shack And Other Big Stocks Moving Higher On Thursday

By Avi Kapoor

February 15, 11:23 AM

U.S. stocks were mostly higher, with the Dow Jones index gaining more than 150 points on Wednesday.

ALB

1 minute read

News

BridgeBio Pharma Presented Additional Clinical Outcomes Data from the Phase 3 ATTRibute-CM Study of Acoramidis in Patients with Transthyretin Amyloidosis Cardiomyopath

By Charles Gross

November 12, 11:43 AM

BridgeBio Pharma, Inc. (NASDAQ:BBIO) (“BridgeBio” or the “Company”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today presented additional Phase 3

BBIO

5 minute read

Options

10 Health Care Stocks Whale Activity In Today’s Session

By Benzinga Insights

November 10, 1:35 PM

This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums…

ABBV

1 minute read

Why Is Biomarin & BridgeBio Pharma Rival Lumos Pharma Stock Trading Higher Today?

By Vandana Singh

November 8, 2:20 PM

Lumos Pharma Inc (NASDAQ: LUMO) announced that topline results from its Phase 2 OraGrowtH210 dose-finding trial and its Phase 2 OraGrowtH212 Pharmacokinetic/Pharmacodynamic (PK/PD) trial met all primary

BBIO

1 minute read

Rare Disease Player BridgeBio Pharma’s Upside Potential Is Significant According to Citi Analyst – Here’s Why

By Vandana Singh

November 7, 5:27 PM

Citi initiated coverage on BridgeBio Pharma Inc (NASDAQ: BBIO), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, noting an optimistic outlook on the stock.

BBIO